TABLE 3.
A summary of chemotherapy for patients where data was available.
| Regimen | Cycles | Stage | Site | Dead/Alive | Survival (days) |
|---|---|---|---|---|---|
| 5-FU | 1 | — | pCCA | Dead | 328 |
| Gemcitabine/Oxaliplatin | 6 | pT3 | pCCA | Dead | 40 |
| Gemcitabine | — | pT2 | pCCA | Dead | 785 |
| Capecitabine | 8 | pT2 | pCCA | Dead | 987 |
| Gemcitabine/Oxaliplatin | 5 | — | — | — | — |
| Capecitabine | 6 | pT3 | iCCA | Alive | — |
| Gemcitabine/Cisplatin | 5 | pT2 | pCCA | Dead | 356 |
| Doxorubicin (chemoembolization) | — | pT1 | iCCA | Dead | 2084 |
| Doxorubicin | — | pT1 | iCCA | Alive | — |
| Doxorubicin | — | pT1 | iCCA | Alive | — |
| Doxorubicin | — | pT1 | iCCA | Alive | — |
| Doxorubicin | — | pT1 | iCCA | Alive | — |
| Doxorubicin | — | pT2 | iCCA | Dead | 328 |
| Doxorubicin | — | pT2 | iCCA | Alive | — |
| Doxorubicin | — | pT2 | iCCA | Alive | — |
| Doxorubicin | — | pT2 | iCCA | Alive | — |
| Doxorubicin | — | pT2 | iCCA | Alive | — |
| Capecitabine | 4 | pT3 | pCCA | Alive | — |
| Capecitabine | — | pT3 | pCCA | Alive | — |